All In Biotech

Drug Trial Radar · NCT07941622

Study of Hexaxim Compared With Pentaxim Administered With a Monovalent Hepatitis B Vaccine in Healthy Chinese Infants.

A Nested Phase 3, Randomized, Active-controlled, Open-label, 2-arm, Multicenter Study to Investigate the Immunogenicity and Safety of Sanofi's Hexavalent DTaP-IPV-HB-PRP~T Combined Vaccine Given at 2, 4, and 6 Months of Age Compared With DTaP-IPV//PRP~T Combined Vaccine (Pentaxim™) Given at 2, 4, and 6 Months of Age Administered With a Monovalent Hepatitis B Vaccine Given at 1 and 6 Months of Age to Healthy Chinese Infants Who Previously Received a Birth Dose of Monovalent Hepatitis B Vaccine

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 720 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

720

Planned (sponsor's estimate)

Start

Dec 28, 2026

Primary completion

Apr 27, 2028

Study completion Jul 30, 2029

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Nov 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 30 days, up to 45 days
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to measure the safety and immunogenicity of Hexaxim given at 2, 4, and 6 MoA compared with Pentaxim given at 2, 4, and 6 MoA plus a monovalent Hep B vaccine given at 1 and 6 MoA in healthy Chinese infants born to HBsAg seronegative mothers. Study details include: * The study duration per participant will be approximately 18 months. * The study vaccines administration: * Group 1: for the primary series vaccination, Hexaxim will be administered 3 doses at 2, 4, and 6 MoA. * Group 2: for the primary series vaccination, Pentaxim will be administered 3 doses at 2, 4, and 6 MoA, and the monovalent Hep B vaccine will be administered at 1 and 6 MoA.

Conditions

  • Haemophilus Influenzae Type b Immunisation
  • Hepatitis B Immunisation
  • Polio Immunization
  • Pertussis Immunisation
  • Diphtheria Immunisation
  • Tetanus Immunisation
  • Healthy Volunteers

Interventions

  • DTaP-IPV-HB-PRP~T combined vaccineBiological

    Pharmaceutical form:Suspension for injection in a pre-filled syringe Route of administration:IM injection

  • DTaP-IPV//PRP~T combined vaccineBiological

    Pharmaceutical form:Freeze-dried PRP\~T in a vial reconstituted with the injectable suspension of DTaP-IPV in a pre-filled syringe Route of administration:IM injection

  • monovalent Hep B vaccineBiological

    Pharmaceutical form: Depending on the brand procured Route of administration:IM injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 1 month after the last dose of primary series (investigational group [Hexaxim: Group 1] and comparator group [Pentaxim and monovalent Hep B: Group 2]) (7 MoA):Time frame: Day181

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.